Gabapentin Capsule
Product Images NDC 70518-3330

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-3330). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Gabapentin 100mg 70518 3330 01)

Gabapentin is a medication that comes in the form of a 100 mg capsule that can only be obtained with a prescription. The NDC number for this product is 70518-3330-01 and it has been manufactured by Ascend Labs, LLC located in Montvale, NJ. The package should be kept out of reach of children and stored at a temperature between 20-26°C (63-77°F), with permissible excursions to 15-30°C (59-86°F). The product has been repackaged by RemedyRepack Inc., based in Indiana, PA. There are no usage instructions available and the product expiration date and lot number are not available.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin is a medication that comes in capsule form, containing 100mg per capsule. It is only available with a prescription (Rx only) and comes in a bottle with 100 capsules. The NDC number for this product is 70518-3330-00, while the manufacturer is Ascend Labs, LLC, located in Montvale, NJ. The medication should be stored at a temperature between 20-26°C (63-77°F), with excursions permittedto 15-30°C (59-86°F) [See USP]. The directions for use can be found in the package insert. The product has been repackaged by RemedyRepack Inc., of Indiana, PA 15701.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

The text describes a table showing the mean pain score during a 4-week dose titration period and a 4-week fixed dose period. The table has two columns: "Placebo" and "Gabapentin, 3600 mg/day". The mean pain score is 10. However, there is no information given on what cause the pain or for what individuals this study was conducted.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

This is a chart showing the mean pain score at baseline and over several weeks during a study. Different doses of gabapentin were given, along with a placebo. There was a titration period and a fixed dose period. Additional information is not available.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

The text describes a figure that shows the percentage of patients who responded to treatment by experiencing a reduction in pain. The figure is divided into ten equally spaced increments, each representing 10% increments from 100% to 0%. The figure is labeled "Figure 3" and is titled "Proportion of Responders (patients with a 250% reduction in pain score) at Endpoint: Controlled PHN Studies". The figure compares the response rate of different studies, and the text shows the percentage of responders for each study. The text also includes statistical information, such as p-values for some studies. Therefore, it is a data analysis report.*

FDA Label Image

Gabapentin-fig4.jpg (Gabapentin Fig4)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.